» Articles » PMID: 37432081

Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer

Abstract

Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA-positive total tumor volume (TTV). Clinical implementation of such software is not expected soon, limiting the use of RECIP in practice. Purpose To assess the agreement of RECIP determined using tumor segmentation software (quantitative RECIP) with RECIP determined by qualitative reads by nuclear medicine physicians (visual RECIP) for response evaluation in metastatic castration-resistant prostate cancer. Materials and Methods This multicenter retrospective study at three academic centers included men who received lutetium 177 (Lu) PSMA treatment between December 2014 and July 2019. PSMA PET/CT images at baseline and 12 weeks were assessed qualitatively by five readers for changes in TTV and for new lesions. Quantitative changes in TTV were also measured using tumor segmentation software. The status of new lesions was combined with qualitative changes in TTV to determine visual RECIP and with quantitative changes in TTV to determine quantitative RECIP. The primary outcomes were the agreement between visual and quantitative RECIP and the interreader reliability of visual RECIP according to the Fleiss κ. The secondary outcome was the association of visual RECIP with overall survival according to Cox regression. Results A total of 124 men (median age, 73 years [IQR, 67-76 years]) were included. Forty (32%) and 84 (68%) men had quantitative RECIP progressive disease (PD) and non-PD, respectively. Agreement between visual versus quantitative RECIP was excellent (κ = 0.89; 118 of 124 men [95%]). Agreement among readers in classifying visual RECIP PD versus non-PD was excellent (κ = 0.81; 103 of 124 men [83%]). RECIP PD was associated with significantly shorter overall survival compared with non-PD (hazard ratio, 2.6 [95% CI: 1.7, 3.8]; < .001). Conclusion Qualitatively assessed RECIP demonstrated excellent agreement with quantitative RECIP and excellent interreader reliability and can be readily implemented in clinical practice for response evaluation in men with metastatic castration-resistant prostate cancer undergoing Lu-PSMA therapy. © RSNA, 2023

Citing Articles

RECIP 1.0 + PSA for response assessment in mCRPC patients treated with Ac / Lu PSMA combination therapy.

Sheikh G, Delker A, Zacherl M, Holzgreve A, Takayama Fouladgar S, Unterrainer M EJNMMI Res. 2025; 15(1):19.

PMID: 40038098 PMC: 11880445. DOI: 10.1186/s13550-025-01211-z.


Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI.

Kersting D, Borys K, Kuper A, Kim M, Haubold J, Goerttler T Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39794510 DOI: 10.1007/s00259-024-07060-7.


Organ-specific response to [Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors.

Bessac D, Baltzinger P, Poterszman N, Pham Van F, Collen C, Malouf G Endocrine. 2024; 87(3):1333-1341.

PMID: 39714577 DOI: 10.1007/s12020-024-04138-y.


Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.

Caracciolo M, Castello A, Castellani M, Bartolomei M, Lopci E Biomedicines. 2024; 12(10).

PMID: 39457667 PMC: 11504290. DOI: 10.3390/biomedicines12102355.


From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer.

Hameed M, Gul M, Chaudhry A, Muzaffar H, Sheikh M, Chee W Cancers (Basel). 2024; 16(17).

PMID: 39272896 PMC: 11394180. DOI: 10.3390/cancers16173039.


References
1.
Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

2.
McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

3.
Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

4.
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel F, Hartenbach M . Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2017; 59(3):469-478. DOI: 10.2967/jnumed.117.198119. View

5.
Nickols N, Anand A, Johnsson K, Brynolfsson J, Borreli P, Parikh N . aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in F-DCFPyL Images of Veterans with Prostate Cancer. J Nucl Med. 2021; 63(2):233-239. DOI: 10.2967/jnumed.120.261863. View